- Home
- GILD vs SHOP Comparison
GILD vs SHOP Comparison
Compare GILD & SHOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | SHOP |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.5B | 164.2B |
| IPO Year | 2000 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GILD | SHOP |
|---|---|---|
| Price | $145.95 | $133.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 33 |
| Target Price | $143.50 | ★ $162.84 |
| AVG Volume (30 Days) | 6.3M | ★ 15.1M |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.28% | N/A |
| EPS Growth | ★ 1684.21 | N/A |
| EPS | ★ 6.78 | 0.94 |
| Revenue | ★ $24,689,000,000.00 | $11,556,000,000.00 |
| Revenue This Year | $4.68 | $29.30 |
| Revenue Next Year | $6.10 | $23.68 |
| P/E Ratio | ★ $21.23 | $138.91 |
| Revenue Growth | 9.98 | ★ 30.14 |
| 52 Week Low | $95.30 | $69.84 |
| 52 Week High | $157.29 | $182.19 |
Technical Indicators
Market Signals| Indicator | GILD | SHOP |
|---|---|---|
| Relative Strength Index (RSI) | 50.89 | 55.13 |
| Support Level | $143.09 | $105.94 |
| Resistance Level | $157.29 | $139.10 |
| Average True Range (ATR) | 3.27 | 7.09 |
| MACD | -1.43 | 2.90 |
| Stochastic Oscillator | 24.02 | 90.09 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About SHOP Shopify Inc.
Shopify offers an e-commerce platform primarily to small and medium-size businesses. The firm has two segments. The subscription solutions segment allows Shopify merchants to conduct e-commerce on a variety of platforms, including the company's website, physical stores, pop-up stores, kiosks, social networks (Facebook), and Amazon. The merchant solutions segment offers add-on products for the platform that facilitate e-commerce and include Shopify Payments, Shopify Shipping, and Shopify Capital.